Irish pharmaceutical firm Warner Chilcott plc (WCRX) announced higher fourth-quarter GAAP net income of $124 million, or $0.49 per share, versus the prior-year quarter's $90 million, or $0.36 per share. Quarterly cash net income or CNI totaled $242 million, a marginal growth, compared with last year's $240 million, while adjusted CNI was $228 million, or $0.91 per share in the recent quarter. On average, 16 analysts polled by Thomson Reuters expected earnings per share of $0.73 for the quarter. Analysts' estimates typically exclude one-time items.
However, total revenue in the quarter slid 5% to $612 million, from $646 million in 2011, hurt by a drop in ACTONEL revenues of $76 million, due in large part to the overall declines in the U.S. oral bisphosphonate market, and the continuing declines in ACTONEL net sales in Western Europe and Canada following the 2010 loss of exclusivity in both regions, and a decline in DORYX net sales of $27 million following the introduction of generic competition for DORYX 150 mg product in early May 2012. The decline was offset, in part, by net sales growth in certain promoted products, primarily ASACOL and LO LOESTRIN FE, according to the company. Analysts estimated revenues of $565.21 million for the quarter.
For comments and feedback: editorial@rttnews.com